NCT02214602View on ClinicalTrials.gov

Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

May 31, 2017

Conditions
Carcinoma of Urinary Bladder, Superficial
Interventions
DRUG

Epirubicin

"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"

Trial Locations (1)

35516

Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT02214602 - Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter